Suanfarma Suanfarma

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"iVeena","sponsor":"Glaukos","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$10.0 million","newsHeadline":"Glaukos Licenses Iveena\u2019s Investigational Keratoconus Therapy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"August 2022","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals for Copper Sulphate Pentahydrate

    Menu

    Copper Sulphate Pentahydrate

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              iVeena

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Glaukos Licenses Iveena’s Investigational Keratoconus Therapy

              Details:

              Under the licensing agreement with Glaukos Corporation that grants Glaukos an exclusive global license to develop and commercialize IVMED-80 (copper sulfate), a pharmacologic treatment for keratoconus.

              Lead Product(s): Copper Sulphate Pentahydrate

              Therapeutic Area: Ophthalmology Product Name: IVMED-80

              Highest Development Status: Phase I/ Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Glaukos

              Deal Size: Undisclosed Upfront Cash: $10.0 million

              Deal Type: Licensing Agreement August 24, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Inke S.A: APIs manufacturing plant.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY